Obesity Treatment Efficacy and Safety Meta-Analysis

A network meta-analysis compares weight loss efficacy and safety of sleeve gastrectomy and pharmacotherapies like tirzepatide. It synthesizes data from 23 randomized controlled trials involving 14,293 participants, published by Zachary Omeh in 2024. The analysis covers trials from 2014 to 2024.

Use Cases

• Compare mean difference in percentage total weight loss (TWL) between interventions like tirzepatide and sleeve gastrectomy.
• Rank treatment safety profiles using adverse event rates from network meta-analysis.
• Analyze confidence intervals (95% CI) and P-scores to assess statistical equivalence of weight loss outcomes.
• Model treatment efficacy hierarchies based on reported metrics for semaglutide, liraglutide, and orlistat.

Strengths

• Analysis based on 23 randomized controlled trials with 14,293 total participants.
• Clear primary outcome metric: percentage change in total body weight with mean differences and confidence intervals.
• Systematic review protocol registered with PROSPERO (ID: CRD420251016726) and adhered to.

Limitations

• Limited to 453.9 KB of summary data, lacking individual patient-level records for deeper analysis.
• Temporal scope may be incomplete as the search covered 2014 to 2024, potentially missing earlier trials.
• Findings are constrained by the methodologies and reporting of the 23 included source trials.

Provenance

Source

Systematic review and network meta-analysis of trials from MEDLINE, EMBASE, and Cochrane CENTRAL.

Collection Method

Pairwise and network meta-analysis of randomized controlled trials comparing obesity treatments.

Time Range

Trials published between 2014 and 2024.

Freshness

Last updated in April 2026, based on a literature search up to 2024.